The naive question: you keep seeing 'co-agonist' in obesity-drug coverage. What does it mean? An agonist is a molecule that switches a receptor on. A co-agonist switches on more than one — with a single molecule.

Here's why that's hard. Each receptor in your body evolved to recognize one specific hormone, like a lock shaped for one key. A co-agonist has to be a single key that opens two or three different locks at once. Designing one molecule with that many right-fitting features is a real feat of protein engineering, and the patent record is where the engineering is spelled out residue by residue.

“A a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors is disclosed. Uses of the triple agonist are disclosed.”— U.S. Patent No. 11,332,508 source

Think of it like a master key cut to work several doors. Each tooth has to be exactly right for its lock, but they all share one body. A co-agonist peptide is engineered the same way — different regions of the same molecule fit different receptors.

The 2022 patents show how that engineering is actually written down as a claim. Hanmi Pharmaceutical's grant US11332508B2 covers a triple agonist hitting the glucagon, GLP-1, and GIP receptors — one key, three locks. What is striking when you read the claim is that the molecule is not described as a fixed sequence but as a template: a backbone of roughly thirty positions where each numbered residue can be one of several listed amino acids. Position 2, for instance, may be a non-standard residue such as α-methyl-glutamic acid or aminoisobutyric acid (Aib) — substitutions that swap out a natural amino acid for a synthetic one. That single choice is doing real work, because the natural backbone is exactly the part the body's enzymes recognize and chew up.

The claim also sets a measurable engineering bar. It does not just say the peptide "works" at three receptors; it specifies an in-vitro activity of about 0.1% or more at each receptor relative to the native hormone, and dependent claims tighten that to 0.8%, 1%, 2% and higher at named combinations. That is the patent equivalent of an engineering tolerance: a way of drawing a boundary around molecules that retain enough of each receptor's signal to count as a genuine triple agonist rather than a single-receptor peptide with trace cross-talk. A separate claim adds a half-life requirement — the peptide must last longer in the body than any of the three native hormones it imitates — which is the difference between a lab curiosity and something dosable.

That last point is where the "acylation" trick comes in, and the second 2022 record makes it explicit. Zealand Pharma's US11395847B2 covers dual GLP-1/GLP-2 agonists — one key, two locks — and its claims hang a fatty-acid chain off a specific lysine on the peptide. The patent spells out the chemistry: a long-chain acyl group such as a 17-carbon or 19-carbon di-acid, often joined through a small spacer (isoGlu, a short PEG unit, or a tiny linker peptide). Functionally, that greasy tail lets the peptide latch onto albumin, the body's most abundant blood protein, which acts like a slow-release reservoir and drags out the molecule's circulating life. So the dual agonist is really two engineering problems solved together: a backbone tuned to fit two receptors, and a chemical anchor tuned to keep it around long enough to act.

Why bother with multiple receptors at all? Because the body's metabolism is controlled by several hormone signals, and a molecule that engages them together can, in principle, do the work that would otherwise need a cocktail of separate drugs. The claims frame this as a engineering choice, not a clinical promise — they recite the receptors, the sequence template, the substitutions, and the potency thresholds, and leave the outcomes to be demonstrated. Reading them, you can see why these molecules are so hard to design and so valuable to lock down: every position on the backbone and every atom of the acyl tail is a separately defensible decision.

It helps to see why the "lock and key" picture undersells the difficulty. Glucagon, GLP-1 and GIP are themselves close cousins — they share an evolutionary backbone — but their receptors discriminate sharply between them. A co-agonist therefore cannot simply average the three native hormones; it has to carry features that each receptor will accept without features that any one of them rejects. That is why the Hanmi claim reads as a long menu of permitted residues at each numbered position rather than a single sequence: the inventors are claiming the whole region of "sequence space" where a working compromise exists, and excluding the much larger region where it does not. Dependent claims that demand 90% or 95% sequence identity to a defined formula are drawing the outer fence of that space.

The records also show two different schools of design sitting side by side in the same year. Hanmi's approach builds the multi-receptor activity into the peptide backbone itself, tuning individual residues. Zealand's acylated dual agonist leans harder on the chemical add-on — the fatty-acid chain and its spacer — to solve the durability half of the problem. Reported as engineering, neither is presented as better; they are two routes to the same pair of goals, fit and longevity, and the patent record captures both being staked out independently.

The short version: a co-agonist is one molecule, multiple receptors. The cleverness is in the engineering — building a single peptide whose numbered positions are each tuned to fit several locks at once, then bolting on a fatty anchor so it survives long enough to matter. The 2022 patent record is where that craft is laid out in full, claim by claim.